Research Article| Volume 29, ISSUE 6, 104682, June 2020

Download started.


Botulinum Toxin Type A for Upper Limb Spasticity in Poststroke Patients: A Meta-analysis of Randomized Controlled Trials


      Background and Aim: Botulinum toxin type A is considered to be an effective antispasmodic in recent years. We assess the effectiveness of botulinum toxin type A for the treatment of poststroke spasticity in the upper extremity using a meta-analysis. Methods: We searched several databases including PubMed, Web of Science, Embase, and Cochrane database for relevant studies, up until October 2017. All randomized controlled trials of botulinum toxin type A treat poststroke upper limb spasticity published were included. The primary outcome measure was modified ashworth score at the elbow, finger and wrist, pain score, and barthel index. Results: Ten randomized controlled trials were identified and reported sufficient data for inclusion in the pooled analysis (n = 950). The results of modified ashworth score at different joints, pain score, barthel index showed no difference was found in the effectiveness of botulinum toxin type A compared with placebo in the treatment of the upper limb spasticity after stroke. But modified ashworth score at the elbow was improver in Dysport subgroups (standardized mean difference [SMD] = −.39, 95%CI = −.67 to −.10, P = .008) compared with Botox subgroups (SMD = .08, 95%CI = −.68 to .83, P = .84). Conclusions: The meta-analysis of these studies showed that the overall effectiveness of botulinum toxin type A does not seem to differ from placebo for poststroke Patients. But the meta-analysis yielded a favorable effect of Dysport compared with placebo based on 4 trials.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Stroke and Cerebrovascular Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Lance J.W.
        The control of muscle tone, reflexes, and movement: Robert Wartenberg Lecture.
        Neurology. 1980; 30: 1303-1313
        • Sommerfeld D.K.
        • Eek E.U.
        • Svensson A.K.
        • et al.
        Spasticity after stroke: its occurrence and association with motor impairments and activity limitations.
        Stroke. 2004; 35: 134
        • Welmer A.K.
        • Widén H.L.
        • Sommerfeld D.K.
        Location and severity of spasticity in the first 1-2weeks and at 3 and 18 months after stroke.
        Eur J Neurol. 2010; 17: 720-725
        • Mizrahi E.M.
        • Angel R.W.
        Impairment of voluntary movement by spasticity.
        Ann Neurol. 1979; 5: 594-595
        • Katrak P.H.
        • Cole A.M.
        • Poulos C.J.
        • et al.
        Objective assessment of spasticity, strength, and function with early exhibition of dantrolene sodium after cerebrovascular accident: a randomized double-blind study.
        Arch Phys Med Rehabil. 1992; 73: 4-9
        • Dashtipour K.
        • Chen J.J.
        • Walker H.W.
        • et al.
        Systematic literature review of abobotulinumtoxinA in clinical trials for adult upper limb spasticity.
        Am J Phys Med Rehab. 2015; 94: 229
        • Bakheit A.M.
        • Pittock S.
        • Moore A.P.
        • et al.
        A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke.
        Eur J Neurol. 2001; 8: 559
        • Bakheit A.M.
        • Thilmann A.F.
        • Ward A.B.
        • et al.
        A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke.
        Stroke. 2000; 31: 2402
        • Brashear A.
        • Gordon M.F.
        • Elovic E.
        • et al.
        Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke.
        N Engl J Med. 2002; 347: 395-400
        • Childers M.K.
        • Brashear A.
        • Jozefczyk P.
        • et al.
        Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke 1 ☆.
        Arch Phys Med Rehabil. 2004; 85: 1063-1069
        • Hesse S.
        • Mach H.
        • Fröhlich S.
        • et al.
        An early botulinum toxin A treatment in subacute stroke patients may prevent a disabling finger flexor stiffness six months later: a randomized controlled trial.
        Clini Rehabil. 2012; 68: 237-245
        • Kaji R.
        • Osako Y.
        • Suyama K.
        • et al.
        Botulinum toxin type A in post-stroke upper limb spasticity.
        Curr Med Res Opin. 2010; 26: 1983-1992
        • Mccrory P.
        • Turner-Stokes L.
        • Baguley I.J.
        • et al.
        Botulinum toxin A for treatment of upper limb spasticity following stroke: a multi-centre randomized placebo-controlled study of the effects on quality of life and other person-centred outcomes.
        J Rehabil Med. 2009; 41: 536
        • Shaw L.
        • Rodgers H.
        • Price C.
        • et al.
        BoTULS: a multicentre randomised controlled trial to evaluate the clinical effectiveness and cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A.
        Health Technol Assess. 2010; 14: 1
        • Shaw L.C.
        • Price C.I.M.
        • Wijck F.M.J.V.
        • et al.
        Botulinum toxin for the upper limb after stroke (BoTULS) trial effect on impairment, activity limitation, and pain.
        Stroke. 2011; 42: 1371
        • Simpson D.M.
        • Alexander D.N.
        • O'Brien C.F.
        • et al.
        Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial.
        Neurology. 1996; 46: 1306-1310
        • Foley N.
        • Pereira S.
        • Salter K.
        • et al.
        Treatment with botulinum toxin improves upper-extremity function post stroke: a systematic review and meta-analysis.
        Arch Phys Med Rehabil. 2013; 94: 977-989
        • Rosales R.L.
        • Chua-Yap A.S.
        Evidence-based systematic review on the efficacy and safety of botulinum toxin-A therapy in post-stroke spasticity.
        J Neural Transm. 2008; 115: 617-623
        • Cardoso E.
        • Rodrigues B.
        • Lucena R.
        • et al.
        Botulinum toxin type A for the treatment of the upper limb spasticity after stroke: a meta-analysis.
        Arq Neuropsiquiatr. 2005; 63: 30
        • Yablon S.A.
        • Brin M.F.
        • Vandenburgh A.M.
        • et al.
        Dose response with onabotulinumtoxinA for post-stroke spasticity: a pooled data analysis.
        Mov Disord. 2011; 26: 209
        • Sun L.C.
        • Chen R.
        • Fu C.
        • et al.
        Efficacy and safety of botulinum toxin type A for limb spasticity after stroke: a meta-analysis of randomized controlled trials.
        BioMed Res Int. 2019;